(资料图片仅供参考)

。作为国内原创一氧化氮分子技术平台，诺令生物INOwill一氧化氮治疗仪已于2022年4月通过了国家药品监督管理局的评审及审批，获国家药监局三类医疗器械注册证。设备通过电化学催化法可即时生成高纯度的一氧化氮气体，随呼吸机同步输送至患者。设备体积小巧(15kg)，解决了传统钢瓶供气设备体积庞大、移动不便的缺点。

- 上下滑动查看参资料-

[1] Rajalakshmi Rajendran, et al. Critical role of nitric oxide inimpeding COVID‑19 transmission and prevention: a promising possibility.Environ Sci Pollut Res Int 2022; 29(26):38657-38672.

[2] S. Akerstrom, et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology 2009; 395:1–9.

[3]G.B. Stefano, et al. Potential immunoregulatoryandantiviral/SARS-CoV-2 activities of nitric oxide. Med Sci Mon 2020;26: e925679.

[4] A. Andreou, et al. COVID-19: the potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2. In Vivo 2020; 34:1567–1588.

[5] Wanyi Fang, et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radical Biology and Medicine 2021;